Compare Oklo Inc (OKLO) vs Summit Therapeutics Inc (SMMT) Price & Performance

OKLO trades at $34.70, down 5.76% in the last 24 hours, with a bearish technical signal from moving averages. The company reported no revenue in 2025 and a net loss of $105.66 million, with a negative net income margin of -12,625.54%. Recent news highlights competition in the nuclear sector and a $1 billion stock sale, while analyst consensus remains bullish with a $78.63 price target.

Outlook: High growth potential in the nuclear energy market, supported by a strong buy rating from analysts. Risks include significant cash burn, lack of revenue, and execution challenges in commercializing reactor technology. The stock's upside depends on successful project deployment and future revenue generation.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.